Gregory L. Ortega

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

H. Kantarjian, S. Verstovsek, R. Paquette, 2013, Journal of Hematology & Oncology.

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts

H. Kantarjian, S. Verstovsek, R. Paquette, 2012 .

Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x109/L.

H. Kantarjian, S. Verstovsek, M. Talpaz, 2012 .

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.

J. Hainsworth, H. Burris, F. Greco, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.